RxDoctor Payments DataLook up a doctor →

Aliaksandr Trusau, MD

Internal Medicine · Green Bay, WINPI 1538542089

Payments from drug & device makers

$1,521,218in general payments, 2019–2025

Across 434 payments — averaging $3505.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.2M
  • Novo Nordisk AS$290K
  • Pfizer$27K
  • Dexcom, Inc.$376
  • Abbott$243
  • Edwards Lifesciences$93
  • plus $48 from 1 others
$14,343in research payments, 2019–2025

Across 15 payments — averaging $956.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$13K
  • Novo Nordisk AS$2K

What the payments were for

  • Speaking & faculty fees$30017%
  • Travel & lodging$61735%
  • Food & beverage$82647%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly37$1,203,446
Novo Nordisk AS378$289,679
Pfizer8$27,335
Dexcom, Inc.5$376
Abbott2$243
Edwards Lifesciences1$93
Amgen3$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,521,218 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$55,753
Medicare patients
207
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$92,262
JardianceEmpagliflozin53$77,345
MounjaroTirzepatide45$67,683
OzempicSemaglutide42$50,718
XareltoRivaroxaban28$31,962
TradjentaLinagliptin29$31,080
JanuviaSitagliptin Phosphate35$27,784
Spiriva RespimatTiotropium Bromide25$19,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,645
TrulicityDulaglutide16$16,629
MyrbetriqMirabegron37$15,679
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$14,863
Semglee (Yfgn) PenInsulin Glargine-Yfgn14$13,612
SymbicortBudesonide/Formoterol Fumarate37$10,534
Spiriva HandihalerTiotropium Bromide19$9,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27,335$92,262101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →